Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.

doi:10.18632/oncotarget.7739

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.

Oncotarget - 5 Apr 2016

Vigneswaran Janani, Tan Yi-Hung Carol, Murgu Septimiu D, Won Brian M, Patton Kathryn Alexa, Villaflor Victoria M, Hoffman Philip C, Hensing Thomas, Hogarth D Kyle, Malik Renuka, MacMahon Heber, Mueller Jeffrey, Simon Cassie A, Vigneswaran Wickii T, Wigfield Christopher H, Ferguson Mark K, Husain Aliya N, Vokes Everett E, Salgia Ravi

Abstract excerpt

This study reviews extensive genetic analysis in advanced non-small cell lung cancer (NSCLC) patients in order to: describe how targetable mutation genes interrelate with the genes identified as variants of unknown significance; assess the percentage of patients with a potentially targetable genetic alterations; evaluate the percentage of patients who had concurrent alterations, previously considered to be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Adenocarcinoma of Lung

Share to Aged

Share to Carcinoma, Non-Small-Cell Lung

Share to Genetic Testing

Share to Genomics

Share to Lung Neoplasms

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 26934441
DOI: 10.18632/oncotarget.7739
PMCID: PMC4951336

Genes

KRAS
ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.PMID 26934441Read ↗

Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.Semantic proximity Read ↗

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.Semantic proximity Read ↗

Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.Semantic proximity Read ↗

Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.Semantic proximity Read ↗

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Semantic proximity Read ↗

Precision medicine and actionable alterations in lung cancer: A single institution experience.Semantic proximity Read ↗

Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.Semantic proximity Read ↗

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).Semantic proximity Read ↗

Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination.Semantic proximity Read ↗

Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscapeSemantic proximity Read ↗

Genomic Testing in Lung Cancer: Past, Present, and Future.Semantic proximity Read ↗

How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.